Are you Dr. Bonner?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 66 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
619 19th St S
Birmingham, AL 35233Phone+1 205-934-6600
Summary
- Dr. James Bonner, MD is a radiation oncologist in Birmingham, Alabama. He is currently licensed to practice medicine in Alabama, Texas, and Arizona. He is affiliated with Children's of Alabama, Cooper Green Hospital, and Birmingham VA Medical Center.
Education & Training
- University of MichiganResidency, Radiation Oncology, 1986 - 1990
- Henry Ford Health/Henry Ford HospitalInternship, Transitional Year, 1985 - 1986
- Wayne State University School of MedicineClass of 1985
Certifications & Licensure
- MI State Medical License 1990 - 2027
- AZ State Medical License 1995 - 2026
- FL State Medical License 1995 - 2026
- MN State Medical License 1991 - 2025
- TX State Medical License 1997 - 2025
- AL State Medical License 1998 - 2024
- American Board of Radiology Radiation Oncology
Clinical Trials
- Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx, Hypopharynx, or Larynx Start of enrollment: 1999 Apr 01
- Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer Start of enrollment: 2002 Sep 01
- Bevacizumab, Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer Start of enrollment: 2006 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- 328 citationsPatterns of Surgical Care of Lung Cancer PatientsAlex G. Little, Valerie W. Rusch, James A. Bonner, Laurie E. Gaspar, Mark R. Green
The Annals of Thoracic Surgery. 2005-12-01 - 1345 citationsRadiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-indu...James A. Bonner, Paul M. Harari, Jordi Giralt, Roger B. Cohen, Christopher U. Jones
The Lancet. Oncology. 2010-01-01 - 99 citationsRefining Patient Selection for Reirradiation of Head and Neck Squamous Carcinoma in the IMRT Era: A Multi-institution Cohort Study by the MIRI Collaborative.Matthew C. Ward, Nadeem Riaz, Jimmy J. Caudell, Neal Dunlap, Derek Isrow
International Journal of Radiation Oncology, Biology, Physics. 2018-03-01
Press Mentions
- Varian Medical : Alabama's Only Proton Therapy Center Treats First Patient with Varian ProBeamMarch 17th, 2020
- The Proton International at UAB Facility Treats First Patient with Proton TherapyMarch 14th, 2020
Grant Support
- Radiosensitization With Recombinant Antibodies To EGFRNational Cancer Institute2002–2005
- Proliferative Response To Radiation And EtoposideNational Cancer Institute1998–2001
- Radiation Therapy VS Anti EGFR Antibody C225 In SCCNational Center For Research Resources2000
- Proliferative Response To Radiation And EtoposideNational Cancer Institute1997–1998
Professional Memberships
- Member